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3070 - TARGETING FREE LIGHT CHAIN (FLC) SECRETIONAND THE UNFOLDED 
PROTEIN RESPONSE IN MYELOMACELLS USING VAN, A COMBINATION OF 
REPURPOSED DRUGS 
 
Multiple Myeloma (MM) is a malignancy of differentiated B cells characterised by>10% 
neoplastic plasma cells in the bone marrow, monoclonal immunoglobulin (whole and/or free 
light chain; FLC) in serum/urine, lytic bone lesions and fractures, anaemia and 
immunodeficiency. Many patients develop renal impairment, predominantly caused by 
elevated serum FLCs secreted by malignant plasma cells. Despite advances in therapy, MM 
remains incurable and novel low toxicity therapies are urgently needed. We have identified a 
repurposed drug combination (VaN) of valproate (anti-epileptic)and niclosamide (anti-
helminthic) with potent tumour selective additive/synergistic anti-MM activity against cell 
lines and primary cells at clinically achievable doses. Mechanism of action studies identified 
that niclosamide targets mitochondria, uncoupling oxidative phosphorylation, causing loss of 
mitochondrial membrane potential and inducing mitochondrial superoxide. Valproate 
potentiated oxidative stress through production of non-superoxide ROS. VaN treatment also 
rapidly inhibited FLC secretion (<2 hrs)from both MM cell lines and primary cells. VaN 
mediated reduction in FLC levels and anti-myeloma activity was also observed in an NSG 
xenograft myeloma model. Early reduction of sFLC is associated with better prognosis. Total 
RNA-seq and mass-spectrometry based proteomics analyses of the acetylome identified that 
VaN modulated several unfolded protein response (UPR) proteins. Induction of UPR was 
confirmed by XBP-1 alternative splicing (XBP-1s), phosphorylation of PERK and expression 
of CHOP. The UPR is triggered by ER stress and is already targeted clinically in MM using 
proteasome inhibitors (e.g. bortezomib). The addition of low-dose (1 nM) bortezomib to VaN 
enhanced induction of UPR and MM cell killing in vitro. In conclusion, we demonstrate that 
VaN and bortezomib combine to potentiate induction of ER stress and the UPR, rapidly 
inhibiting FLC secretion and enhancing MM cell death 
 
